Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 10/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | BCL9 | O00512 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | STAT6 | P42226 | 3/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119726 | 0.94 | TRPM8 (0.41) | TRPM8PPARGPPARAHTR2AHTR2C | |
| SCHEMBL1119719 | 0.88 | TRPM8 (0.37) | TRPM8PPARGPPARAHTR2AHTR2C | |
| SCHEMBL1120016 | 0.82 | TRPM8 (0.38) | TRPM8PPARGPPARAHTR2AHTR2C | |
| SCHEMBL2248626 | 0.81 | TRPV1 (0.39) | KMT2A | |
| SCHEMBL2248634 | 0.81 | TRPV1 (0.39) | KMT2A | |
| SCHEMBL1120040 | 0.81 | TRPV1 (0.39) | KMT2A | |
| SCHEMBL1120042 | 0.81 | TRPV1 (0.39) | KMT2A | |
| SCHEMBL3087699 | 0.79 | TRPM8 (0.43) | TRPM8PPARGPPARANR1H4KMT2A | |
| SCHEMBL3229865 | 0.78 | PPARG (0.37) | TRPM8PPARGPPARAHTR2ANR1H4 | |
| SCHEMBL3226412 | 0.78 | BCL9 (0.39) | TRPM8PPARGPPARABCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999000-B2 | N-(2-amino-phenyl)-acrylamides | HOFFMANN-LA ROCHE INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2280940-A1 | NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009138338-A1 | NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286848-A1 | NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286848-A1 | NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES | MKI67, CCNA2, CCNA1 | TRPM8 4248/4885PPARG 1057/4885PPARA 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.